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INTRODUCTION
Haemophilus influenzae type b (Hib) was an important cause
of bacterial meningitis and other serious invasive diseases
among children aged <5 yr before the introduction of the
Hib conjugate vaccines (1). A dramatic decrease in Hib dis-
ease burden was noted in countries that introduced the Hib
conjugate vaccine into routine immunization schedules (2).
Four basic different types of conjugate vaccines have been
licensed for use in infants against Hib diseases. These vaccines
differ in the carrier proteins, structure and length of the cap-
sular polysaccharide molecule, polyribosylribitol phosphate
(PRP) and the method of conjugating the carrier protein to
the polysaccharide. The first conjugate produced was the diph-
theria toxoid conjugate (PRP-D), followed by mutant diph-
theria toxin conjugate (PRP-CRM), meningococcal outer
membrane protein conjugate (PRP-OMP) and tetanus toxoid
conjugate (PRP-T). Hib conjugate vaccines have been shown
to be highly efficacious against invasive Hib disease and safe
in clinical trials (3-5). 
Vaccine efficacy of Hib vaccines are assessed in correlation
with the level of production of specific anti-PRP IgG (6). An
anti-PRP level ≥1.0 mg/mL is considered predictive for long-
term protection from invasive disease in a vaccinated popu-
lation (7). Based on this, the WHO recommendations on
evaluating the efficacy of Hib conjugate vaccines have been
released, e.g. effective vaccines induce ≥1.0 mg/mL of anti-
PRP antibody in 70% or more of infants 1 month after com-
pletion of the primary immunization series (8).
With the known safety and proven effectiveness of the Hib
conjugate vaccines, WHO recommends it to be included in
all routine infant immunization programs, regardless lack of
local surveillance data (9). By the end of the year 2005, Hib
vaccines were included in the routine infant immunization
program in 101 out of 192 WHO member countries (10).
However, it is not yet introduced into the national immuniza-
tion program in Korea. To make important decisions on the
policy for Hib vaccination, a nationwide study on the epidemi-
ologic status in relation to the disease burden of invasive Hib
diseases as well as cost-effectiveness study is urgent. Also, the
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Immunogenicity of Haemophilus influenzae Type b Conjugate 
Vaccines in Korean Infants: A Meta-analysis
A meta-analysis was performed on the immunogenicity of Haemophilus influenzae
type b (Hib) conjugate vaccines after 2 (2 and 4 months) and 3 doses (2, 4, and 6
months) in Korean infants. A database search of MEDLINE, KoreaMed, and Kore-
an Medical Database was done. The primary outcome measure was the proportion
of infants with anti-polyribosylribitol phosphate (PRP) concentrations ≥1.0 mg/mL.
Eight studies including eleven trials were retrieved. One trial reported on the diph-
theria toxoid conjugate vaccine (PRP-D) and 2 trials each on the mutant diphtheria
toxin (PRP-CRM) and Neisseria meningitidis outer-membrane protein (PRP-OMP)
conjugate vaccine. Heterogeneity in study designs between trials on PRP-CRM was
noted and one trial reported on a monovalent and another on a combination PRP-
OMP vaccine. Thus, a meta-analysis was conducted only on the tetanus toxoid con-
jugate vaccine (PRP-T). After a primary series of 2 doses and 3 doses, 80.6% (95%
confidence interval [CI]; 76.0-85.1%) and 95.7% (95% CI; 94.0-98.0%) of infants
achieved an antibody level ≥1.0 mg/mL, respectively. The immunogenic response
to the PRP-T vaccine was acceptable after a primary series of 3 doses and also 2
doses. A reduced number of doses as a primary series could be carefully consid-
ered in Korean infants.
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appropriate schedule should be determined. 
The Hib vaccination schedule differs between countries in
number of doses and periods of vaccination. At present, the
current recommendations for the vaccination schedule for
Hib vaccine in Korea is that the primary series be given at
2, 4 and 6 months of age for the PRP-T and PRP-CRM vac-
cine and at 2 and 4 months of age for the PRP-OMP vaccine,
with a following booster dose at 12-15 months of age for all
three types of vaccines. Although all countries give a booster
dose of the Hib vaccine, some countries recommend 2 doses
as a primary series, whereas other countries recommend 3
doses before 12 months of age. 
The objective of this study was to evaluate the immuno-
genicity of a primary series of Hib conjugate vaccines in Kore-
an infants through a meta-analysis. We will therefore deter-
mine whether the immunologic responses are acceptable after
3 doses (given at 2, 4, and 6 months of age) and also after 2
doses (given at 2 and 4 months of age) of the Hib conjugate
vaccine.
MATERIALS AND METHODS
Literature search
MEDLINE, KoreaMed, and the Korean Medical Data-
base were searched for all studies of Hib conjugate vaccine
in Korean children. The search included terms in the title or
key words, applying the terms ‘Haemophilus influenzae type b’,
‘Hib’, ‘vaccination OR vaccine’ and ‘immunogenicity’. Also,
a manual search of studies was done on studies referenced in
publications identified through the initial search and experts
on Hib vaccine in Korea were contacted for unpublished data
or ongoing studies.
Selection criteria
We included all clinical trials that reported immunogenici-
ty results following a primary series (immunization at 2, 4,
and 6 months of age) of Hib conjugate vaccine in healthy
Korean infants. The primary outcome measure was the sero-
conversion rate after Hib conjugate vaccine. Seroconversion
rate was defined as the proportion of infants achieving ≥1
mg/mL of anti-PRP antibody 4-12 weeks after vaccination.
The seroconversion rate after 2 doses and the one after 3 doses
of the Hib conjugate vaccine injected according to the rec-
ommended schedule or designed trial protocol were evalu-
ated. Studies reporting natural anti-PRP antibody levels or
antibody persistence after Hib vaccine were excluded.
Data extraction
Data from each of the studies were extracted independent-
ly into a data extraction form by two investigators. Any dis-
agreements were resolved by discussion. Major extraction vari-
ables in the form included the years of the publication and
the study conduction, type of conjugate vaccine, vaccination
schedule, age of enrollment, duration of follow up, method
of evaluation of immunogenicity and results of immunogenic
responses. 
Fig. 1. QUOROM flow diagram.
7 studies excluded
2 Review
1 Vaccination status
3 Natural immunity
1 data not extractable
42 studies excluded
21 Hib disease
13 antibiotic resistance
8 diagnosis and laboratory research
5 trials excluded from meta-analysis
1 PRP-D; only 1 trial
2 PRP-CRM; data not comparable
(data at different number of doses)
2 PRP-OMP; data not comparable
1 trial on monovalent vaccine
1 trial on combination vaccine
Meta-analysis done on 6 trials of PRP-T
5 trials include data on immunogenicity after 2 doses
5 trials include data on immunogenicity after 3 doses
8 studies (including 11 trials) reviewed
1 trial on PRP-D
2 trials on PRP-CRM
6 trials on PRP-T
2 trials on PRP-OMP
57 total studies identified
52 studies identified by database search
4 studies by handsearch
1 study by contact with an expert
1 study included 3 trials
2 trials on PRP-CRM
1 trial on PRP-T
1 study included 2 trials
1 trial on PRP-T
1 trial on PRP-OMP
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Statistical analysis
The seroconversion rate was calculated together with the
95% confidence interval (CI) for each trial and they were
pooled across the trials by the inverse variance method (11).
A chi-square statistic was calculated to assess statistical het-
erogeneity across the trials. When the extent was considered
to be significantly large (P value of <0.10), a random effects
model was also considered (12). According to the WHO Tech-
nical Report Series, effective Hib vaccines have been found
to induce ≥1.0 mg/mL anti-PRP antibody in 70% or more
of the infants 1 month after the completion of the primary
immunization series (8). We assessed whether the lower 95%
CI of the pooled seroconversion rate in infants vaccinated would
exceed this criterion after a primary series of 2 doses and 3
doses of the Hib conjugate vaccine.
RESULTS
Identification of studies and trials
The process of study inclusion is summarized in Fig. 1
according to the Quality of Reporting of Meta-analyses (QU-
OROM) guidelines (13). Fifty-seven studies were identified;
52 by electronic database search, four studies by handsearch,
and one unpublished study was obtained through contact
with an expert on Hib vaccine. Among these studies, fifteen
studies relevant to the Hib conjugate vaccine in Korean chil-
dren were retrieved. Seven out of these studies were exclud-
ed: two publications were review articles of the Hib vaccine,
one study reported on the policy of Hib vaccines in Korea,
three studies focused on natural antibody titers and antibody
persistence in children and one study of a PRP-T conjugate
vaccine did not include data for seroconversion. Eight studies
were finally included in the review (14-20). Among these
eight studies, one study included three different trials and
another study reported on two different trials. Thus the iden-
tified trials to be reviewed were 11 in total. The characteris-
tics of the included studies are shown in Table 1. 
Description of the trials
PRP-D
There was one trial on the immunogenicity of the PRP-
D vaccine. The proper regimen for the primary series of the
PRP-D vaccine is vaccination at 2, 4, and 6 months of age.
The trial reported on the immunologic response after 2 doses
and 3 doses of the vaccine. The seroconversion rate after 2
doses and 3 doses of the vaccine reported 26.3% and 57.9%,
respectively (Table 2).
PRP-CRM
Two trials on the PRP-CRM vaccine were identified. One
trial reported the immunogenic response after a total of three
doses (given at age 2, 4, and 6 months) and another trial re-
ported data after 1 dose and 2 doses of a primary series of the
PRP-CRM vaccine and before and after a booster dose of the
vaccine. Thus, data were not comparable between the two
trials. According to the data reported in both trials, the sero-
conversion rate after the PRP-CRM vaccine showed a low
response after 2 doses but with the 3rd dose, the seroconver-
sion rate increased up to 100%. However, there was only one
report each after 2 doses and 3 doses of the PRP-CRM vac-
cine with a limited number of subjects in both trials.
PRP-OMP
There were two trials reporting immunogenicity of the
Number in brackets designate different trials in one publication.
*4 months (after 1 dose); 
� 6 months (after 2 dose).
mo, months; wks, weeks. 
Author
(Ref. No.)
Publication Study period
No. of
infants
Vaccine
Age of
enrollment
Sched-
ule
Route
Laboratory
method
Blood
sample
Choi SY (14) 1999 Feb. 1994-July 1995 42 PRP-D 2 mo 2, 4, 6 IM 2, 6, 7, 15, 16 mo Farr assay
Lee HJ
[1] Unpublished 1992 32 PRP-CRM 2 mo 2, 4, 6 IM 2, 7 mo Farr assay
Lee HJ
[2] Unpublished 1992 49 PRP-CRM 2 mo 2, 4, 6 IM 2, 4, 6, 15-23 mo Farr assay
Lee HJ
[3] Unpublished 1992 61 PRP-T 2 mo 2, 4, 6 IM 2, 4, 6, 15-23 mo Farr assay
Yoo ES (15) 1995 May 1992-July 1993 34 PRP-T 2 mo 2, 4, 6 IM 2, 4, 6, 9 mo ELISA
Kim JS (16) 1996 NA 40 PRP-T 6-10 wks 2, 4, 6 IM 2, 6, 8 mo Farr assay
Chung EH (17) 2003 March 2001-April 2002 63 PRP-T 2 mo 2, 4, 6 IM 2, 6, 7 mo ELISA
Kim KH (18)
[1] 2008 March 2005-Nov. 2005 59*, 90
� ,  PRP-T 6-12 wks 2, 4, 6 IM 2, 4*, 6
� , 7 mo ELISA
149 (43-91 days)
Kim KH (18)
[2] 2008 March 2005-Nov. 2005 72 PRP-OMP 6-12 wks 2, 4 IM 2, 4, 5 mo ELISA
(43-91 days)
Yang PS (19) 2002 Dec. 1999-May 2001 120 PRP-T 2 mo 2, 4, 6 IM 7-8, 19-20 mo Farr assay
Chung EH (20)  2006 Jan. 2004-June 2005 58 PRP-OMP+ 2 mo 2, 4 IM 2, 4, 6 mo ELISA
Hepatitis B (42-84 days)
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PRP-OMP vaccine. However, the vaccines included in the
trials were different in character, one reported the immuno-
genicity of a monovalent PRP-OMP vaccine whereas the
other trial reported on a combination vaccine, PRP-OMP+
Hepatitis B. A good immunologic response up to 91.7% and
96.6% after 2 doses was observed in the trial of the mono-
valent PRP-OMP vaccine and the combination vaccine, res-
pectively. 
PRP-T
There were six trials reporting the seroconversion rate after
vaccination with the PRP-T vaccine at 2, 4, and 6 months of
age. Among these trials, one trial did not evaluate the sero-
conversion rate after 2 doses and one trial did not have data
after 3 doses. 
Immunogenicity of Hib conjugate vaccines: a meta-
analysis
Six trials reported on the immunogenicity of the PRP-T
conjugate vaccine. Data from a total of 288 and 394 children
were included in the meta-analysis of the seroconversion rate
after 2 doses and 3 doses of the PRP-T vaccine, respectively. 
The seroconversion rate for the PRP-T vaccine after 2 doses
from 5 trials ranged from 78.0% to 85.0%. The pooled sero-
conversion rate was 80.6% (95% CI; 76.0-85.1%). There was
no statistically significant heterogeneity (P>0.1, c2=1.573).
The seroconversion rate for the PRP-T vaccine after 3 doses
from 5 trials ranged from 87.5% to 98.4%. The pooled sero-
conversion rate was 95.9% (95% CI; 93.5-97.5%). There
was statistically significant heterogeneity in the outcomes
(P<0.1, c2=9.72) (Fig. 2). To account for the statistical het-
erogeneity, we also tried a random effects model, of which
the pooled estimate 95.4% (95% CI, 92.5-97.6%) showed
little difference.
DISCUSSION
The results of the meta-analysis on the immunogenicity of
Fig. 2. Forest plot of seroconversion rate and 95% CI of individual trials of the PRP-T conjugate vaccine: (A) after 2 doses, (B) after 3 doses. 
0.0 50.0 100.0
Combined (95% CI) 80.56% (75.98-85.13%)
Test for Heterogeneity Chi
2=1.573 (P>0.1)
Yoo ES (15)
Kim JS (16)
Lee HJ
[3]
Chung EH (17)
Kim KH (18)
[1]
Combined
A
0.0 50.0 100.0
Combined (95% CI) 95.9% (94.0-98.0%)
Test for Heterogeneity Chi
2=9.72 (P<0.1)
Yoo ES (15)
Kim JS (16)
Chung EH (17)
Kim KH (18)
[1]
Yang PS (19)
Combined
B
Number in brackets designate different trials in one publication.
*4 months (after 1 dose); 
� 6 months (after 2 dose).
mo, months. 
Study
(Ref. No.)
Vaccine No. of infants
Antibody levels (mg/mL) at age
4 mo 
(after 
1 dose)
2 mo
(pre)
6 mo 
(after 
2 dose)
7-9 mo 
(after
3 dose)
% of infants with antibody ≥1.0 mg/mL
4 mo 
(after 
1 dose)
6 mo 
(after
2 dose)
7-9 mo
(after
3 dose)
Choi SY (14) PRP-D 42 0.07 0.19 1.39 26.3% 57.9%
Lee HJ
[1] PRP-CRM 32 0.07 14.9 100%
Lee HJ
[2] PRP-CRM 49 0.12 0.13 1.32 2.0% 47.0%
Lee HJ
[3] PRP-T 61 0.10 0.81 5.13 38.0% 84.0%
Yoo ES (15) PRP-T 34 0.15 0.64 6.62 22.0 48.7% 82.4% 95.5%
Kim JS (16) PRP-T 40 0.14 11.5 20.3 85.0% 87.5%
Chung EH (17) PRP-T 63 0.17 4.14 14.7 77.7% 98.4%
Kim KH (18)
[1] PRP-T 59*, 90
� , 149 <0.15 0.91* 4.46
� 15.0 42.4%* 78.9%
� 97.3%
Yang PS (19) PRP-T 120 24.6 98.3%
Kim KH (18)
[2] PRP-OMP 72 <0.15 0.98 7.78 52.8% 91.7%
Chung EH (20) PRP-OMP+ 58 <0.15 1.96 10.02 63.2% 96.6%
Hepatitis B
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the PRP-T vaccine demonstrate that the PRP-T conjugate
vaccines are highly immunogenic in Korean infants. After a
primary series of PRP-T conjugate vaccine given at 2, 4, and
6 months of age, 80.6% and 95.9% of the infants had anti-
PRP antibody levels ≥1.0 mg/mL after the second dose and
third dose, respectively. According to this study, the lower
limit of 95% CI after 2 doses was 76.0%, which is higher
than the WHO recommendations for effective Hib conju-
gate vaccines (8). Thus, infants after 2 doses (given at 2 and
4 months of age) of PRP-T have responses considered accept-
able for effectiveness of prevention of disease. Although there
was no significant heterogeneity between the results of the
trials after 2 doses of the PRP-T vaccine, heterogeneity was
noted in the results of trials after 3 doses. This mainly came
from one study which showed a seroconversion rate of 87.5%,
whereas the other four studies ranged from 95.5% to 98.4%.
However, a seroconversion rate of 87.5% is also allowable
according to the definition of an effective Hib vaccine and
the result of that single study does not affect the conclusion
that the vaccine is effective after 3 doses. The small sample
size of the study did not have a critical impact on the pooled
seroconversion rate. 
There was only one trial on the PRP-D. PRP-D is well
known for its limited immunogenicity in infants and the
report in Korean infants showed data comparable to previ-
ous reports in other countries (6). According to the results
of the PRP-CRM, it seems that there is a low response after
2 doses and a significant boosting effect after the 3rd dose.
However, considering there was only one trial each after 2
doses and 3 doses of the PRP-CRM it is not appropriate to
make any conclusions on the response. The PRP-OMP vac-
cine showed good immunologic responses after 2 doses of
both a monovalent PRP-OMP vaccine and a combination
vaccine with the Hepatitis B. Further studies related with
these vaccines in Korean children are needed.
According to the results of this study, we can carefully con-
sider the possibility adopting of a 2-dose primary schedule.
The results of the meta-analysis are acceptable after 2 doses
and there is evidence in previous reports supporting a 2-dose
primary schedule. According to a report on methods of econ-
omization of the Hib vaccine, immunogenicity, longevity of
anti-PRP antibody response and immunologic memory of a
2-dose regimen was comparable with a 3-dose regimen (21).
In a meta-analysis of vaccine efficacy against invasive Hib
disease, the protective efficacy was 82% (odds ratio=0.18,
95% CI; 0.04-0.74) for two doses (5). Vaccines in these stud-
ies included PRP-T, PRP-D and PRP-OMP. When excluding
the PRP-D trial, which showed no efficacy after the vaccine,
the efficacy was 100% and 93% after 2 doses of PRP-T and
PRP-OMP, respectively (22, 23). In a review of four different
Hib vaccines and vaccination strategies of infants in Scandi-
navia, the effectiveness of PRP-CRM and PRP-T was excel-
lent regardless of the schedule or number of primary doses.
Two doses at various ages before 12 months were adminis-
tered as a primary series in Denmark, Finland (since 1988),
Norway and Sweden compared with 3 doses in Iceland and
Finland (1986-1987), and no difference in clinical effective-
ness was observed (24). Also, in a comparison of five differ-
ent vaccination schedules with PRP-T, although there was a
significant difference in anti-PRP antibody concentrations
between a 2-dose and 3-dose schedule, they concluded that
two injections of PRP-T vaccine were immunogenic enough
to maintain protection up to 12 to 24 months of age (25). It
is not desirable to apply a policy based on data of other coun-
tries or different regions, especially considering the possibil-
ity of different vaccine responses related to ethnicity and nat-
ural boosting. But these data can be valuable sources for ref-
erence, particularly considering the local epidemiology of
these countries of the Scandinavian region were higher than
reports in Korea (26). 
There is little doubt as to the need of the booster dose in
the Hib conjugate vaccination schedule. An increase of reports
on vaccine failures in the UK were seen where the Hib vacci-
nation program did not include a booster dose (27), whereas
there is no increase in vaccine failures in countries were rou-
tine boosting is done (28). Thus, we can carefully consider
the possibility of adopting a 2-dose primary schedule with a
booster. Moreover, we have to think of the impact of a 2-dose
primary schedule. With the high cost of the vaccine, more
children in the Korean population could be able to receive a
vaccine compared with a 3-dose primary schedule. The Hib
conjugate vaccination rate, up to January 2007 is approxi-
mately 65.2% and 54.8% for the primary series and booster
dose in Korean children (unpublished data). Although an
analysis on the cost benefit of the Hib vaccine in Korea should
be done, a 2-dose primary schedule could lower the nation-
wide health cost related to the vaccine, making it feasible to
adopt the Hib conjugate vaccine into the national immuniza-
tion program. 
An important issue on considering the possibility of a 2-
dose schedule is that this could be applicable to the PRP-T
vaccine, which we evaluated through a meta-analysis and the
PRP-OMP vaccine, which is already licensed for 2 doses. To
apply this policy to other types of Hib conjugate vaccines
and especially combination vaccines, further studies on the
immunogenicity are needed.
There are some limitations to this study. The effect of the
Hib conjugate vaccine is reviewed based on immunologic
results. Among the clinical trials included in the analysis,
there were no studies that reported cases of vaccine failure or
the effect of the vaccine compared with a placebo or control.
However, this limitation can be overcome by the fact that the
anti-PRP antibody level is widely used in evaluating vaccine
efficacy for the Hib vaccine (7, 27, 29). Also, experimental
data supports the use of anti-PRP antibody responses as a sur-
rogate of clinical vaccine efficacy (30). Two characteristics of
the anti-PRP antibodies play a major role in protection against
diseases; anti-PRP antibodies are opsonic and activate com-Meta-analysis of Immunogenicity of Hib Conjugate Vaccines in Korean Infants 95
plement-mediated bactericidal activity. 
The antibody threshold for protection against invasive Hib
diseases was derived from data on the unconjugated PRP
polysaccharide vaccine. Since immunological memory and
antibody avidity maturation are well known immunologic
characteristics of conjugate vaccines, the protective antibody
threshold could be an overestimate. Evidence for this is seen
in previous efficacy trials of the Hib conjugate vaccine. In
Finland, even though only 40% of infants immunized with
PRP-D at 3, 4, and 6 months of age developed anti-PRP anti-
body concentrations ≥1.0 mg/mL measured 1 month after
the third dose, vaccine efficacy was 90% (6). In Navajo infants
immunized with PRP-OMP at 2 and 4 months, vaccine effi-
cacy was 95%, despite the fact that only 59% developed anti-
PRP antibody concentrations ≥1.0 mg/mL (23). When using
a threshold that might have the possibility of underestimat-
ing protective efficacy, conclusions made based on this thresh-
old can be safe.
A better way to evaluate the efficacy of the Hib vaccine,
next to a well designed randomized controlled efficacy trial,
would be to directly evaluate the bactericidal activity of the
anti-PRP antibodies elicited. There was one trial among those
included in the meta-analysis which reported the results of
a serum bactericidal assay (18). According to the results, anti-
PRP IgG titers correlated well with bactericidal activity for
both PRP-T and PRP-OMP vaccines. Also both vaccines
showed comparable bactericidal activity after 2 and 3 doses
of vaccine in infants. However, because the serum bacterici-
dal assay is difficult and tedious to perform, it is not as wide-
ly used in laboratories as the ELISA. 
The Hib vaccination schedule varies in countries in associ-
ation with the disease burden, cost benefit and national poli-
cy. With the worldwide data showing that invasive Hib dis-
ease has been practically eliminated in many countries, and
considering the demonstrated safety of the vaccine, it should
be promptly adopted to the national immunization program
in Korea. Based on the results of a meta-analysis, we can say
that Korean infants show a good response to Hib conjugate
vaccines and a reduced number of doses as a primary series
could be carefully considered.
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